Identifying immune system defects in children with lymphoma
Immunodeficiency and Cancer: Identification of Congenital Immune System Defects Underlying Paediatric Lymphomas
This study is trying to find out if certain immune system problems in children are linked to types of lymphoma, like non-Hodgkin's lymphoma, to help improve how we diagnose and treat these kids.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 1 Day to 24 Years |
| Sex | All |
| Sponsor | Meyer Children's Hospital IRCCS Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Bologna and 3 other locations) |
| Trial ID | NCT06332196 on ClinicalTrials.gov |
What this trial studies
This study focuses on understanding the link between congenital immune system defects and pediatric lymphomas, particularly non-Hodgkin's lymphoma. It aims to analyze biological samples and clinical data from patients diagnosed with Hodgkin's or non-Hodgkin's lymphoma, with or without signs of immune dysregulation. By identifying genetic variants associated with inborn errors of immunity, the study seeks to improve diagnosis and treatment strategies for these patients. The research is crucial as it addresses the complexities of distinguishing between benign and malignant conditions in the context of immune deficiencies.
Who should consider this trial
Good fit: Ideal candidates include children diagnosed with Hodgkin's or non-Hodgkin's lymphoma who exhibit signs of immune dysregulation or have a family history of immunodeficiency.
Not a fit: Patients with known genetic diseases or those who do not consent to participate in the study may not receive any benefit.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and tailored treatments for children with lymphoma linked to immune deficiencies.
How similar studies have performed: While this approach is novel in its specific focus on pediatric lymphomas and immune deficiencies, preliminary analyses have shown promise in identifying genetic variants in related conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a clinical diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NEIL) with or without signs of immune dysregulation (lymphoproliferation, autoimmunity, hypogammaglobulinaemia, family history of immunodeficiency). * Patients with previous HL or NEIL lymphoma who have developed, concomitantly with the tumour or subsequently, clinical manifestations mentioned above attributable to a congenital defect of immunity. Exclusion Criteria: * Patients with known genetic diseases, or who do not consent to participate in the study
Where this trial is running
Bologna and 3 other locations
- AOU Malpighi IRCCS — Bologna, Italy (Active_not_recruiting)
- Meyer Children's Hospital IRCCS — Florence, Italy (Recruiting)
- AOU Pisana — Pisa, Italy (Active_not_recruiting)
- Ospedale Pediatrico Bambin Gesù IRCCS — Roma, Italy (Active_not_recruiting)
Study contacts
- Principal investigator: Eleonora Gambineri — Meyer Children's Hospital IRCCS
- Study coordinator: Eleonora Gambineri
- Email: eleonora.gambineri@meyer.it
- Phone: 0555662624
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.